Receptor mediated disruption of retinal pigment epithelium function in acute glycated-albumin exposure

Experimental Eye Research

Volumn 137, Issue , 2015, Pages 50-56

  Dahrouj, Mohammad ^a   Desjardins, Danielle M ^a   Liu, Yueying ^a   Crosson, Craig E ^a   Ablonczy, Zsolt ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AGE; Alb; Barrier; Blood retina barrier; Diabetes; DME; FhRPE; Glyc alb; OCT; PBS; Rabbit; RAGE; Retinopathy; RPE; TEER; VEGF; VEGF R2

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLYCOSYLATED ALBUMIN; VASCULOTROPIN RECEPTOR 2; GLYCOSYLATED SERUM ALBUMIN; SERUM ALBUMIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DUTCH BELTED (RABBIT); HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; TIME LAPSE IMAGING; TISSUE CULTURE; ANIMAL; BLOOD RETINA BARRIER; CADAVER; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MACULAR EDEMA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT;

ANIMALS; BLOOD-RETINAL BARRIER; CADAVER; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MACULAR EDEMA; RABBITS; RETINAL PIGMENT EPITHELIUM; SERUM ALBUMIN; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84936806863     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2015.06.004     Document Type: Article

References (50)

1. Ablonczy Z., Crosson C.E. VEGF modulation of retinal pigment epithelium resistance. Exp. Eye Res. 2007, 85:762-771.
2. Ablonczy Z., Dahrouj M., Tang P.H., Liu Y., Sambamurti K., Marmorstein A.D., Crosson C.E. Human retinal pigment epithelium cells as functional models for the RPE invivo. Investig. Ophthalmol. Vis. Sci. 2011, 52:8614-8620.
3. Ablonczy Z., Prakasam A., Fant J., Fauq A., Crosson C., Sambamurti K. Pigment epithelium-derived factor maintains retinal pigment epithelium function by inhibiting vascular endothelial growth factor-R2 signaling through gamma-secretase. J.Biol. Chem. 2009, 284:30177-30186.
4. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N.Engl. J. Med. 1994, 331:1480-1487.
5. Antonetti D.A., Barber A.J., Hollinger L.A., Wolpert E.B., Gardner T.W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J.Biol. Chem. 1999, 274:23463-23467.
6. Bakri S.J., Kaiser P.K. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am. J. Ophthalmol. 2005, 139:290-294.
7. Bandello F., Berchicci L., La Spina C., Battaglia Parodi M., Iacono P. Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res. 2012, 48(Suppl.1):16-20.
8. Bandello F., Brancato R., Menchini U., Virgili G., Lanzetta P., Ferrari E., Incorvaia C. Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy. Semin. Ophthalmol. 2001, 16:12-18.
9. Bandello F., Pognuz R., Polito A., Pirracchio A., Menchini F., Ambesi M. Diabetic macular edema: classification, medical and laser therapy. Semin. Ophthalmol. 2003, 18:251-258.
10. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
11. Dahrouj M., Alsarraf O., Liu Y., Crosson C.E., Ablonczy Z. C-type natriuretic peptide protects the retinal pigment epithelium against advanced glycation end product-induced barrier dysfunction. J.Pharmacol. Exp. Ther. 2013, 344:96-102.
12. Dahrouj M., Alsarraf O., McMillin J.C., Liu Y., Crosson C.E., Ablonczy Z. Vascular endothelial growth factor modulates the function of the retinal pigment epithelium invivo. Investig. Ophthalmol. Vis. Sci. 2014, 55:2269-2275.
13. Deane R., Singh I., Sagare A.P., Bell R.D., Ross N.T., LaRue B., Love R., Perry S., Paquette N., Deane R.J., Thiyagarajan M., Zarcone T., Fritz G., Friedman A.E., Miller B.L., Zlokovic B.V. Amultimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J.Clin. Investig. 2012, 122:1377-1392.
14. Ding J., Wong T.Y. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr. Diabetes Rep. 2012, 12:346-354.
15. Duncan K.G., Bailey K.R., Kane J.P., Schwartz D.M. Human retinal pigment epithelial cells express scavenger receptors BI and BII. Biochem. Biophys. Res. Commun. 2002, 292:1017-1022.
16. Forbes J.M., Cooper M.E. Mechanisms of diabetic complications. Phys. Rev. 2013, 93:137-188.
17. Frank R.N. Diabetic retinopathy. N.Engl. J. Med. 2004, 350:48-58.
18. Gibran S.K., Sachdev A., Stappler T., Newsome R., Wong D., Hiscott P. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br. J. Ophthalmol. 2007, 91:602-604.
19. Higai K., Shimamura A., Matsumoto K. Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin. Chim. Acta Int. J. Clin. Chem. 2006, 367:137-143.
20. Ho A.C., Scott I.U., Kim S.J., Brown G.C., Brown M.M., Ip M.S., Recchia F.M. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology 2012, 119:2179-2188.
21. Howes K.A., Liu Y., Dunaief J.L., Milam A., Frederick J.M., Marks A., Baehr W. Receptor for advanced glycation end products and age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2004, 45:3713-3720.
22. Kakehashi A., Inoda S., Mameuda C., Kuroki M., Jono T., Nagai R., Horiuchi S., Kawakami M., Kanazawa Y. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. Diabetes Res. Clin. Pract. 2008, 79:438-445.
23. Kenyon B.M., Voest E.E., Chen C.C., Flynn E., Folkman J., D'Amato R.J. Amodel of angiogenesis in the mouse cornea. Investig. Ophthalmol. Vis. Sci. 1996, 37:1625-1632.
24. Kiernan D.F., Mieler W.F. The use of intraocular corticosteroids. Expert Opin. Pharmacother. 2009, 10:2511-2525.
25. Klaassen I., Van Noorden C.J., Schlingemann R.O. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog. Retin. Eye Res. 2013, 34:19-48.
26. Kurihara T., Westenskow P.D., Bravo S., Aguilar E., Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J.Clin. Investig. 2012, 122:4213-4217.
27. Ma W., Lee S.E., Guo J., Qu W., Hudson B.I., Schmidt A.M., Barile G.R. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Investig. Ophthalmol. Vis. Sci. 2007, 48:1355-1361.
28. Marmor M.F., Negi A. Pharmacologic modification of subretinal fluid absorption in the rabbit eye. Arch. Ophthalmol. 1986, 104:1674-1677.
29. McFarlane S., Glenn J.V., Lichanska A.M., Simpson D.A., Stitt A.W. Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. Br. J. Ophthalmol. 2005, 89:107-112.
30. Monnier V.M., Sell D.R., Nagaraj R.H., Miyata S., Grandhee S., Odetti P., Ibrahim S.A. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992, 41(Suppl.2):36-41.
31. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J.Biol. Chem. 1992, 267:14998-15004.
32. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S.J., Robinson G.S., Adamis A.P., Shima D.T. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 2007, 171:53-67.
33. Oishi A., Yamashiro K., Tsujikawa A., Ooto S., Tamura H., Nakata I., Miyake M., Yoshimura N. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 2013, 251:1-7.
34. Ozaki H., Hayashi H., Vinores S.A., Moromizato Y., Campochiaro P.A., Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp. Eye Res. 1997, 64:505-517.
35. Pedram A., Razandi M., Levin E.R. Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. J.Biol. Chem. 2002, 277:44385-44398.
36. Peyroux J., Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol. Biol. 2006, 54:405-419.
37. Ryeom S.W., Silverstein R.L., Scotto A., Sparrow J.R. Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. J.Biol. Chem. 1996, 271:20536-20539.
38. Saint-Geniez M., Maharaj A.S., Walshe T.E., Tucker B.A., Sekiyama E., Kurihara T., Darland D.C., Young M.J., D'Amore P.A. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE 2008, 3:e3554.
39. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
40. Stewart M.W., Grippon S., Kirkpatrick P. Aflibercept. Nat. Rev. Drug Discov. 2012, 11:269-270.
41. Stitt A.W., Bhaduri T., McMullen C.B., Gardiner T.A., Archer D.B. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell Biol. Res. Commun. 2000, 3:380-388.
42. Stitt A.W., Moore J.E., Sharkey J.A., Murphy G., Simpson D.A., Bucala R., Vlassara H., Archer D.B. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Investig. Ophthalmol. Vis. Sci. 1998, 39:2517-2523.
43. Tarr J.M., Kaul K., Chopra M., Kohner E.M., Chibber R. Pathophysiology of diabetic retinopathy. Int. Sch. Res. Netw. Ophthalmol. 2013, 2013:13.
44. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell. Mol. Biol. 1998, 44:1013-1023.
45. Tranos P.G., Wickremasinghe S.S., Stangos N.T., Topouzis F., Tsinopoulos I., Pavesio C.E. Macular edema. Surv. Ophthalmol. 2004, 49:470-490.
46. Xu H.Z., Le Y.Z. Significance of outer blood-retina barrier breakdown in diabetes and ischemia. Investig. Ophthalmol. Vis. Sci. 2011, 52:2160-2164.
47. Yamada Y., Ishibashi K., Bhutto I.A., Tian J., Lutty G.A., Handa J.T. The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas. Exp. Eye Res. 2006, 82:840-848.
48. Yamagishi S., Nakamura K., Matsui T. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr. Drug Discov. Technol. 2006, 3:83-88.
49. Yokoi M., Yamagishi S.I., Takeuchi M., Ohgami K., Okamoto T., Saito W., Muramatsu M., Imaizumi T., Ohno S. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br. J. Ophthalmol. 2005, 89:673-675.
50. Yu J., Liu F., Cui S.J., Liu Y., Song Z.Y., Cao H., Chen F.E., Wang W.J., Sun T., Wang F. Vitreous proteomic analysis of proliferative vitreoretinopathy. Proteomics 2008, 8:3667-3678.